PTC Therapeutics, Inc.: director Michael Schmertzler sold 2,500 shares

What happened Michael Schmertzler, a director, sold a total of 2,500 shares in two open-market transactions on Oct 14, 2026: 2,118 shares at $59.52 for $126,063 and 382 shares at $60.14 for $22,973, totaling $149,036.

Key details

• Transaction date and prices: Oct 14, 2026; 2,118 shares at a weighted average of $59.52 (trades ranged $58.85 to $59.82) and 382 shares at a weighted average of $60.14 (trades ranged $59.87 to $60.54).
• Shares owned after the transaction: not specified in the filing.
• Footnotes: the filing states the sales were effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P. on May 14, 2026; the shares sold are reported as held by Section Six Partners, L.P., of which the reporting person is a general partner and limited partner, and the reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
• Filing date: Oct 16, 2026 (report period Oct 14, 2026).

Why it may matter

• The filing reports open-market sales effected under a Rule 10b5-1 plan and notes the involvement of an affiliated investment vehicle (Section Six Partners, L.P.).
• This was not an option exercise, an award, or a gift according to the filing.
  A filing does not show why the insider traded or why the company acted.